Show simple item record

dc.contributor.authorPerambakam, Supriya
dc.contributor.authorXie, Hui
dc.contributor.authorEdassery, Seby
dc.contributor.authorPeace, David J.
dc.date.accessioned2012-06-27T22:19:57Z
dc.date.available2012-06-27T22:19:57Z
dc.date.issued2010
dc.identifier.bibliographicCitationPerambakam, S., Xie, H., Edassery, S., & Peace, D. J. 2010. Long-term follow-up of HLA-A2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the prostate specific antigen peptide homologue (PSA146-154). Clinical and Developmental Immunology, 2010: 473453. doi 10.1155/2010/473453en
dc.identifier.issn1740-2522
dc.identifier.other[doi] 10.1155/2010/473453
dc.identifier.urihttp://hdl.handle.net/10027/8404
dc.descriptionCopyright © 2010 Supriya Perambakam et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. doi 10.1155/2010/473453en
dc.description.abstractTwenty eight HLA-A2+ patients with high-risk, locally advanced or metastatic, hormone-sensitive prostate cancer were immunized with a peptide homologue of prostate specific antigen, PSA146-154, between July 2002 to September 2004 and monitored for clinical and immune responses. Fifty percent of the patients developed strong PSA146-154-peptide specific delayed type hypersensitivity skin responses, tetramer and/or IFN-γ responses within one year. Thirteen patients had stable or declining serum levels of PSA one year post-vaccination. A decreased risk of biochemical progression was observed in patients who developed augmented tetramer responses at six months compared to pre-vaccination levels (p=0.02). Thirteen patients have died while 15 patients remain alive with a mean overall survival of 60 months (95% CI, 51 to 68 months) per Kaplan-Meier analysis. A trend towards greater overall survival was detected in men with high-risk, hormone-sensitive CaP who developed specific T-cell immunity following vaccination with PSA146-154 peptide.en
dc.description.sponsorshipThe clinical trial was funded by grants from the National Cancer Institute (CA88062) and the Department of Army (DAMD17-98-1-8489). Funding for conducting correlative studies was supported by grants from the Illinois Department of Public Health (IDPH 4328301) and the Milheim Grant for Cancer Research, Denver, CO (award# 2007-24). Statistical analysis was made possible by a grant from the National Center for Research Resources (grant # UL1RR029879) awarded to the Center for Clinical and Translational Science, University of Illinois at Chicago.en
dc.language.isoen_USen
dc.publisherHindawi Publishing Corporationen
dc.subjectPSA146-154 peptideen
dc.subjectVaccineen
dc.subjecthigh-risk prostate canceren
dc.subjecthormone-sensitive prostate canceren
dc.subjecttetrameren
dc.subjectIFN-gammaen
dc.subjectoverall survivalen
dc.subjectserum PSAen
dc.subjectdelayed type hypersensitivity skin responsesen
dc.subjectgene expression profileen
dc.titleLong-term follow-up of HLA-A2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the prostate specific antigen peptide homologue, PSA146-154en
dc.typeArticleen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record